Evidence map›Paper›PMID 35448514›Full record

ReviewMetabolites2022

New Therapeutics Targeting Arterial Media Calcification: Friend or Foe for Bone Mineralization?

Astrid Van den Branden, Anja Verhulst, Patrick C D'Haese, Britt Opdebeeck

Open access · goldAbstract readReview
In one paragraph

Review in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. [Long noncoding RNA H19 promotes vascular calcification by repressing the Bax inhibitor 1/optic atrophy 1 pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Astrid Van den BrandenLaboratory of Pathophysiology, Department Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0001-6325-4997
Anja VerhulstLaboratory of Pathophysiology, Department Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
Patrick C D'HaeseLaboratory of Pathophysiology, Department Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0003-1463-6571
Britt OpdebeeckLaboratory of Pathophysiology, Department Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-9379-2718
University of Antwerp · BE

Funding

Research Foundation - Flanders 12Z0422NResearch Foundation - Flanders 1SD9222N
6 · The paper itself

Abstract

The presence of arterial media calcification, a highly complex and multifactorial disease, puts patients at high risk for developing serious cardiovascular consequences and mortality. Despite the numerous insights into the mechanisms underlying this pathological mineralization process, there is still a lack of effective treatment therapies interfering with the calcification process in the vessel wall. Current anti-calcifying therapeutics may induce detrimental side effects at the level of the bone, as arterial media calcification is regulated in a molecular and cellular similar way as physiological bone mineralization. This especially is a complication in patients with chronic kidney disease and diabetes, who are the prime targets of this pathology, as they already suffer from a disturbed mineral and bone metabolism. This review outlines recent treatment strategies tackling arterial calcification, underlining their potential to influence the bone mineralization process, including targeting vascular cell transdifferentiation, calcification inhibitors and stimulators, vascular smooth muscle cell (VSMC) death and oxidative stress: are they a friend or foe? Furthermore, this review highlights nutritional additives and a targeted, local approach as alternative strategies to combat arterial media calcification. Paving a way for the development of effective and more precise therapeutic approaches without inducing osseous side effects is crucial for this highly prevalent and mortal disease.

Indexed as

arterial calcificationbone metabolismcell deathchronic kidney diseasenutritionoxidative stressphenotypic transitionvascular therapy

Identifiers

PMID35448514
PMCPMC9027727
OpenAlexW4224312075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.